Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
“We are delighted to attract a corporate leader with such an outstanding record of achievement,” stated
“I am truly excited to join the seasoned group of professionals at Pearl working to bring new, high quality therapies to patients with serious respiratory diseases,” stated Mr. Karsen. “Pearl’s line of products will offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing therapeutics to achieve better clinical outcomes.”
As Pearl Therapeutics’ new Chief Executive Officer,
About Pearl Therapeutics, Inc.
Pearl is developing a portfolio of meaningfully differentiated products to treat respiratory diseases including COPD and asthma. Using its proprietary particle technology, formulation expertise, and unparalleled development experience, Pearl is rapidly advancing a pipeline of products that will offer alternatives to patients and healthcare professionals, ones that better meet their needs, and intend to improve disease management and quality of life.
Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and
Contacts: Pearl Therapeutics Adrian Smith 650.305.2605 For Pearl Therapeutics Jennifer Larson 415.725.2017 email@example.com
SOURCE Pearl Therapeutics